Boston Scientific has launched its WaveWriter Alpha Spinal Cord Stimulator (SCS) portfolio in Europe. The WaveWriter Alpha portfolio consists of four MRI implantable pulse generators (IPGs), enabling expanded personalised treatment based on a patient’s needs.
The devices offer access to waveforms covering different areas of chronic pain, simultaneously layering paraesthesia and paraesthesia-free options and supporting up to 32 contacts targeting specific nerves along the spinal cord.
The WaveWriter Alpha devices come in rechargeable and non-rechargeable options and offer bluetooth which enables faster programming from a distance of up to 3 metres between the patient and the programmer.
Maulik Nanavaty, Senior Vice President and President, Neuromodulation, Boston Scientific, said that: "The launch of the WaveWriter Alpha SCS Systems in Europe represent a significant step forward in the treatment of chronic pain.”
"By unifying our portfolio of SCS devices and offering the latest therapy advances, we remain committed to advancing meaningful innovation, providing both physicians and patients access to the full benefits of our entire portfolio of devices."
Jan Vesper, M.D. Ph.D., Department of Functional Neurosurgery and Stereotaxy at the University Hospital of Düsseldorf, commented: "Being able to offer my patients different therapy options is important because it provides them with pain relief that can maintain long-term results.”
“The combination of different therapy features that promote simplicity like the WaveWriter Alpha SCS Systems enable enhanced personalisation in the advanced treatment of chronic pain."